A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510076-31-00

Enrollment

Registered

2024-06-14

Start date

2025-01-30

Completion date

Unknown

Last updated

2024-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous malformation

Brief summary

Change in NRS score 12 months after treatment start with enalapril compared to baseline.

Detailed description

Volume change on MRI 12 months after treatment start with enalapril compared to baseline., Change in Quality of life 12 months after treatment start with enalapril compared to baseline., Register adverse events > or equal to grade 2 and side effects continues during the study

Interventions

DRUGEnalapril Viatris 5 mg comprimidos EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in NRS score 12 months after treatment start with enalapril compared to baseline.	—

Secondary

Measure	Time frame
Volume change on MRI 12 months after treatment start with enalapril compared to baseline., Change in Quality of life 12 months after treatment start with enalapril compared to baseline., Register adverse events > or equal to grade 2 and side effects continues during the study	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026